Insulin resistance is a common metabolic abnormality that is associated with an increased risk of both atherosclerosis and type 2 diabetes. The phenotype of insulin resistance includes a dyslipidemia characterized by an elevation of very low-density lipoprotein triglyceride, a reduction in high-density lipoprotein cholesterol, and the presence of small, triglyceride-enriched low-density lipoproteins. The underlying metabolic abnormality driving this dylipidemia is an increased assembly and secretion of very low-density lipoprotein particles, leading to an increased plasma level of triglyceride. Hypertriglyceridemia, in turn, results in a reduction in the high-density lipoprotein level and the generation of small, dense low-density lipoproteins; these events are mediated by cholesteryl ester transfer protein. In addition, hypertension, obesity, and a prothrombotic state are also integral components of the insulin resistance syndrome. In this review, we will provide a pathophysiologic basis, based on studies on humans and in tissue culture, for the dyslipidemia of insulin resistance. We will also review the effects of insulin resistance on the coagulation and fibrinolytic pathways. It is hoped that this review will allow health professionals better to evaluate and treat their patients with insulin resistance, thereby reducing the very much increased risk of atherosclerotic cardiovascular disease carried by these individuals.
KennySJAubertREGeissLS.Prevalence and incidence of insulin-dependent diabetes. In: Diabetes in America.Bethesda, MD: National Institutes of Health; 1995. pp. 47–67.
2.
GeissLSHermanWHSmithPJ.Mortality in non-insulin-dependent diabetes. Diabetes in America.Bethesda, MD: National Institutes of Health, 1995: 233–257.
3.
NCEP Expect Panel.Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med1988; 148: 36–69.
4.
Summary of the second report of the National Cholesterol Education Program (NCEP)expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA1993; 269: 3015–3023.
5.
Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care1989; 12: 573–579.
6.
Barrett-ConnorEOrchardTJ.Diabetes and heart disease. In: Diabetes in America.Washington, DC: US Government Printing Office; 1985.
7.
ReavenGMChenY-D.Role of insulin in regulation of lipoprotein metabolism in diabetes. Diabetes Metab Rev1988; 4: 639–652.
8.
ReavenGM.Role of insulin resistance in human disease. Diabetes1988; 37: 1595–1607.
9.
This is a detailed overview of the insulin resistance syndrome, also called syndrome X. It reviews the data linking insulin resistance to diabetes, dyslipidemia, and hypertension.
10.
Juhan-VagueIAlessiMVagueP.Increased plasma PAI-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetol1991; 34: 457–462.
11.
DavidsonPCAlbrinkMJ.Insulin resistance in hyperglyceridemia. Metabolism1965; 14: 1059–1070.
12.
ReavenGMLernerRLSternMPFarquharJW.Role of insulin in endogenous hypertriglyceridemia. J Clin Invest1967; 46: 1756–1767.
13.
OlefskyJMFarquharJWReavenGM.Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med1974; 57: 551–560.
14.
OlefskyJReavenGMFarquharJW.Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest1974; 53: 64–76.
15.
AlbrinkMJKraussRMLindgrenFTVon der GroebenVDWoodPDS.Intercorrelations among high density lipoproteins, obesity, and triglycerides in a normal population. Lipids1980; 15: 668–678.
16.
LawsAHoenHMSelbyJVSaadMFHaffnerSMHowardBV.Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Artheroscler Thromb Vasc Biol1997; 17: 64–71.
17.
A very large body of data from the IRAS study showing that the suppression of plasma free fatty acid levels is directly related to the degree of insulin resistance. Correlations between insulin resistance and other lipid/lipoprotein factors are presented as well.
18.
HowardBVMayer-DavisEJGoffDZaccaroDJLawsARobbinsDCRelationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and Non-Hispanic Whites: the Insulin Resistance Atherosclerosis Study. Metabolism1998; 47: 1174–1179.
19.
SigurdssonGNicollALewisB.Metabolism of very low density lipoproteins in hyperlipidemia: studies of apolipoprotein B kinetics in man. Eur J Clin Invest1976; 6: 167–177.
20.
KissebahAHAlfarsiSEvansDJAdamsPW.Integrated regulation of very-low-density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes1982; 31: 217–225.
21.
An important paper showing that type II diabetes is characterized by an increased hepatic secretion of VLDL triglyceride and apoB.
22.
GinsbergHGrundySM.Effect of caloric restriction on very low density lipoprotein triglyceride metabolism in subjects with diabetes mellitus. Diabetologia1982; 23.421–425.
23.
HowardBVReitmanJSVasquezBZechL.Very-low density lipoprotein triglyceride metabolism in non- insulin-dependent diabetes mellitus: relationship to plasma insulin and free fatty acids. Diabetes1983; 32: 271–276.
24.
Yki-JarvinenHTaskinenM-R.Interrelationship among insulin's antilipolytic and glucoregulatory effects and plasma triglycerides in nondiabetic and diabetic patients with endogenous hypertriglyceridemia. Diabetes1988; 37: 1271–1278.
25.
CabezasM Castrode BruinTWde ValkHWShouldersCCJansenHErkelensD. WillemImpaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest1993; 92: 160–168.
26.
BodenG.Fatty acids and insulin resistance. Diabetes Care1996; 19: 394–395.
27.
One of a series of papers by this investigator demonstrating the effects of an elevated level of free fatty acids on insulin resistance in normal and diabetic subjects.
28.
BodenGChenX.Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest1995; 96: 1261–1268.
29.
BodenGChenXRuizJWhiteJVRossettiL.Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest1994; 93: 2438–2446.
30.
GinsbergHN.Lipoprotein physiology in nondiabetic and diabetes states. Diabetes Care1991; 14: 839–855.
31.
TaskinenM-RPackardCJShepherdJ.Effect of insulin therapy on metabolic fate of apolipoprotein B- containing lipoproteins in NIDDM. Diabetes1990; 39: 1017–1027.
32.
LewisGFUffelmanKDSzetoLWSteinerG.Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes1993; 2: 833–842.
33.
One of the first studies to show, in vivo, that hyperinsulinemia could reduce the secretion of VLDL into the plasma. In addition, this work showed that obese individuals were resistant to the effect of insulin on VLDL secretion.
34.
LewisGFUffelmanKDSzetoLWWellerBSteinerG.Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest1995; 95: 158–166.
35.
MalmstromRPackardCJWatsonTDRannikoSCaslakeMBedfordDMetabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol1997; 17: 1454–1464.
36.
MalmstromRPackardCJCaslakeMBedfordDStewartPYki-JarvinenHEffects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes1998; 47: 779–787.
37.
MalmstromRPackardCJCaslakeMBedfordDStewartPYki-JarvinenHDefective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia1997; 40: 454–462.
38.
KernPA.Lipoprotein lipase and hepatic lipase. Curr Opin Lipidol1991; 2: 162–169.
39.
TaskinenM-R.Lipoprotein lipase in diabetes. Diabetes Metab Rev1987; 3: 551–570.
40.
BrunzellJDPorteDJBiermanEL.Reversible abnormalities in postheparin lipolytic activity during the late phase of release in diabetes mellitus (postheparin lipolytic activitiy in diabetes). Metabolism1975; 24: 1123–1137.
41.
AbramsJJGinsbergHGrundySM.Metabolism of cholesterol and triglycerides in nonketotic diabetes mellitus. Diabetes1982; 31: 903–910.
42.
DammermanMSandkuijlLAHalaasJLChungWBreslowJL.An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA1993; 90: 4562–4566.
43.
LiWWDammermanMMSmithJDMetzgerSBreslowJLLeffT.Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest1995; 96: 2601–2605.
44.
ChenMBreslowJLLiWLeffT.Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res1994; 35: 1918–1924.
45.
ChaitAAlbersJJBrunzellJD.Very low density lipoprotein overproduction in genetic forms of hypertriglyceridemia. Eur J Clin Invest1980; 10: 17–22.
46.
One of several papers (see refs [41–44]) demonstrating increased rates of hepatic secretion of both apoB and TG in patients with combined hyperlipidemia.
47.
TengBSnidermanADSoularAKThompsonGR.Metabolic basis of hyperapobetalipoproteinemia: turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia. J Clin Invest1986; 77: 663–672.
48.
JanusEDNicollAWoottonRTurnerPRMagillPJLewisB.Quantitative studies of very low density lipoprotein: conversion to low density lipoprotein in normal controls and primary hyperlipidaemic states and the role of direct secretion of low density lipoprotein in heterozygous familial hypercholesterolaemia. Eur J Clin Invest1980; 10: 149–159.
49.
KissebahAHAlfarsiAAdamsPW.Integrated regulation for very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipidemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism1981; 20: 856–868.
50.
KissebahAHAlfarsiSEvansDJ.Low density lipoprotein metabolism in familial combined hyperlipdemia: mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis1984; 4: 614–624.
51.
EgusaGBeltzWFGrundySMHowardBV.Influence of obesity on the metabolism of apolipoprotein B in humans. J Clin Invest1985; 76: 596–603.
52.
KissebahAHAlfarsiSAdamsPWSeedMFolkardJWynnV.Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglycerideaemia. Atherosclerosis1976; 24: 199–218.
53.
The first paper demonstrating an increased free fatty acid flux linked to increased VLDL triglyceride secretion in patients with hypertriglyceridemia.
54.
FranklinBGinsbergHHagueWUGinsberg-FellnerF.Very low density lipoprotein metabolism in lipoatrophic diabetes. Metabolism1984; 33: 814–819.
55.
HowardBVAbbottWFBeltzFHarperITFieldsRMGrundySMIntegrated study of low density lipoprotein metabolism and very low density lipoprotein in non-insulin-dependent diabetes. Metabolism1987; 36: 870–877.
56.
TaskinenM-RBeltzWFHarperIFieldsRMSchonfeldGGrundySMThe effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism: studies before and after sulfonylurea therapy. Diabetes1986; 35: 1268–1277.
57.
OlofssonSOBjursellGBostromKCarlssonPElovsonJProtterAAApolipoprotein B: structure, biosynthesis and role in the lipoprotein assembly process. Atherosclerosis1987; 68: 1–17.
58.
DixonJLGinsbergHN.Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J Lipid Res1993; 34: 167–179.
59.
A complete review of the regulation of the hepatic assembly and secretion of apoB-containing lipoproteins. In particular, the post-transcriptional regulation of apoB secretion is detailed.
60.
PullingerCRNorthJDTengB-BRificiVAde BritoAE RonhildScottJ.The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of the mRNA half-life. J Lipid Res1989; 30: 1065–1076.
61.
MoberlyJBColeTGAlpersDHSchonfeldG.Oleic acid stimulation of apolipoprtein B secretion from HepG2 and Caco-2 cells occurs post-transcriptionally. Biochim Biophys Acta1990; 1042: 70–80.
62.
DashtiNWilliamsDLAlaupovicP.Effects of oleate and insulin on the production rates and cellular mRNA concentrations of apolipoproteins in HepG2 cells. J Lipid Res1989; 30: 1365–1373.
63.
SegrestJPJonesMKMishraVKAnantharamaiahGMGarberDW.ApoB-100 has a pentapartite structure composed of three amphipathic alpha-helical domains alternating with two amphipathic beta-strand domains. Detection by the computer program LOCATE. Arterioscler Thromb1994; 14: 1674–1685.
64.
YangC-YGuZWengSAKimTWChenSHPownallHJStructure of apolipoprotein B-100 of human low density lipoproteins. Arteriosclerosis1989; 9: 96–108.
65.
SchekmanR.Polypeptide translocation: a pretty picture is worth a thousand words. Cell1996; 87: 593–595.
66.
BorénJWettestenMSjöbergAThorlinTBondjersGWiklundOThe assembly and secretion of ApoB 100 containing lipoproteins in Hep G2 cells. Evidence for different sites for protein synthesis and lipoprotein assembly. J Biol Chem1990; 265: 10556–10564.
67.
DixonJLChattapadhyayRHuimaTRedmanCMBanerjeeD.Biosynthesis of lipoprotein: location of nascent apoAI and apoB in the rough endoplasmic reticulum of chicken hepatocytes. J Cell Biol1992; 117: 1161–1169.
68.
DavisRAThriftRNWuCCHowellKE.Apolipoproteih B is both integrated into and translocated across the endoplasmic reticulum membrane. Evidence for two functionally distinct pools. J Biol Chem1990; 265: 10005–10011.
69.
FurukawaSSakataNGinsbergHNDixonJLStudies of the sites of intracellular degradation of apolipoprotein B in Hep G2 cells. J. Biol Chem1992; 267: 22630–22638.
70.
YeungSJChenSHChanL.Ubiquitin-proteasome pathway mediates intracellular degradation of apolipoprotein B. Biochemistry1996; 35: 13843–13848.
71.
The first paper showing that apoB was ubiquitinated and degraded by the proteasome (see ref [63] below).
72.
FisherEAZhouMMitchellDMWuXOmuraSWangHThe degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70. J Biol Chem1997; 272: 20427–20434.
73.
SparksJDSparksCE.Insulin modulation of hepatic synthesis and secretion of apolipoprotein B by rat hepatocytes. J Biol Chem1990; 265: 8854–8862.
74.
SparksJDSparksCE.Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim Biophys Acta1994; 1215: 9–32.
75.
An excellent review of the regulation of apoB secretion by insulin.
76.
SparksCEPhungTLBologninoM.Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes. Biochem J1996; 313: 567–574.
77.
SparksJDZolfaghariRSparksCESmithHCFisherEA.Impaired hepatic apolipoprotein B and E translation in streptozotocin diabetic rats. J Clin Invest1992; 89: 1418–1430.
78.
DuerdenJMGibbonGF.Restoration in vitro of normal rates of very-low-density lipoprotein triacylglycerol and apoprotein B secretion in hepatocyte cultures from diabetic rats. Biochem J1993; 294: 167–171.
79.
HollenbeckCBChenY-DGreenfieldMSLardinoisCKReavenGM.Reduced plasma high density lipoprotein-cholesterol concentrations need not increase when hyperglycemia is controlled with insulin in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab1986; 62: 605–608.
80.
GordonTCastelliWPHjortlandMCKannelWBDawberTR.Diabetes blood lipids and the role of obesity in coronary heart disease risk for women. The Framingham study. Ann Int Med1977; 87: 393–397.
81.
UusitupaMSiitonenOVoutilainenEAroAHersioKPyoralaKSerum lipids and lipoproteins in newly diagnosed non-insulin-dependent (type II) diabetic patients with special reference to factors influencing HDL-cholesterol and triglyceride levels. Diabetes Care1986; 9: 17–22.
82.
LaaksoMSarlundHMykkanenL.Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis1990; 10: 223–231.
83.
TallAR.Plasma lipid transfer proteins. J Lipid Res1986; 27: 361–367.
84.
BagdadeJDLaneJTSubbaiahPVOttoMERitterMC.Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus. Atherosclerosis1993; 104: 69–77.
85.
HorowitzBSGoldbergIJMerabJVanniTRamakrishnanRGinsberg •HN.Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest1993; 91: 1743–1752.
86.
The first paper demonstrating that apo AI was dissociable from HDL isolated from patients with hypertriglyceridemia. This work provided a biophysical and physiologic basis for the increased fractional catabolism of apo AI in patients with a high triglyceride level.
87.
LamarcheBUffelmanKDCarpentierALewisGF.Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-1 in healthy men. J Clin Invest1999; 103: 1191–1199.
88.
LamarcheBUffelmanKDSteinerGBarrettPHLewisGF.Analysis of particle size and lipid composition as determinants of the metabolic clearance of human high density lipoproteins in a rabbit model. J Lipid Res1999; 39: 1162–1172.
89.
JonesRJOwensDBrennanCCollinsPBJohnsonATomkinGH.Increased esterification of cholesterol and transfer of cholesteryl ester to apo B-containing lipoproteins in type 2 diabetes: relationship to serum lipoproteins A-I and A-II. Atherosclerosis1999; 119: 151–157.
90.
TanKCCooperMBLingKLGriffinBAFreemanDJPackardCJFasting and posptrandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance. Atherosclerosis1999; 113: 273–287.
91.
FalkoJMO'DorisioTMCatalandS.Improvement of high-density lipoprotein-cholesterol levels: ambulatory type I diabetics treated with the subcutaneous insulin pump. JAMA1982; 247: 37–39.
92.
HarnoKNikkilaEAKuusiT.Plasma HDL-cholesterol and postheparin plasma hepatic endothelial lipase (HL) activity: relationship to obesity and non-insulin dependent diabetes (NIDDM). Diabetes1982; 31: 126–131.
93.
EckelRHAlbersJJCheungMCWahlPWLindgrenFTBiermanEL.High-density lipoprotein composition in insulin-dependent diabetes mellitus. Diabetes1981; 30: 132–138.
94.
GolayAZechLShiM-Z.High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: measurement of HDL turnover using tritiated HDL. J Clin Endocrinol Metab1987; 65: 512–518.
95.
LeN-AGibsonJCGinsbergHN.Independent regulation of plasma apolipoprotein CII and CIII concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res1988; 29: 669–677.
96.
NicollAMillerNELewisB.High density lipoportein metabolism. In: Advances in lipid research.New York: Academic Press, 1980. pp. 53–106.
97.
BrintonEAEisenbergSBreslowJL.Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest1991; 87: 536–544.
98.
KissebahAH.Low density lipoprotein metabolism in non-insulin-dependent diabetes mellitus. Diabetes Metab Rev1987; 3: 619–651.
99.
A comprehensive review of LDL metabolism in diabetes.
100.
HowardBV.Lipoprotein metabolism in diabetes mellitus. J Lipid Res1987; 28: 613–628.
101.
SuzukiNOikawaSHoriSFujiiYSakumaEKotakeHAppearance of multidisperese low density lipoprotein and altered lipoprotein composition in non-insulin-dependent diabetes with type IIa hyperlipoproteinemia. Metabolism1989; 38: 225–229.
102.
FeingoldKRGrunfeldCPangMDoerrlerWKraussRM.LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb1992; 2: 1496–1502.
103.
ReavenGMChenY-DJeppesenJMaheuxPKraussRM.Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest1993; 92: 141–146.
104.
AustinMASelbyJV.LDL subclass phenotypes and the risk factors of the insulin resistance syndrome. Int J Obes Relat Metab Disord1995; 19: S22–S26.
105.
AustinMAMykkanenLKuusistoJEdwardsKLNelsonCHaffnerSMProspective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation1995; 92: 1770–1778.
106.
AustinMABreslowJLHennekensCHBuringJEKraussRM.Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA1988; 260: 1917–1921.
107.
AustinMAKingMDVranizanKMKraussRM.Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation1990; 82: 495–506.
108.
AustinMAHokansonJE.Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein (a) as risk factors for coronary heart disease. Med Clin North Am1994; 78: 99–115.
109.
ChaitABrazgRLTribbleDLKraussRM.Suspectibility of small, dense, low-density, lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med1993; 94: 350–356.
110.
de-GraafJHendriksJCDemackerPNStalenhoefAF.Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after Clofibrate treatment. Arterioscler Thromb1993; 13: 712–719.
111.
ChaitABiermanELAlbersJJ.Low density lipoprotein receptor activity in cultured human skin fibroblasts: mechanism of insulin-induced stimulation. J Clin Invest1979; 64: 1309–1319.
112.
StreicherRKotzkaJMuller-WielandDSiemeisterGMunckMAvciHSREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I. J Biol Chem1996; 271: 7128–7133.
113.
BrindleyDNSalterAM.Hormonal regulation of the hepatic low density lipoprotein receptor and the catabolism of low density lipoproteins: relationship with the secretion of very low density lipoproteins. Prog Lipid Res1991; 30: 349–360.
114.
GinsbergHNLeN-AGibsonJC.Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss. J Clin Invest1985; 75: 614–623.
115.
BiermanELAtherogenesis in diabetes. Arterioscler Thromb1999; 12: 647–656.
116.
SchneiderDJSobelBE.Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA1999; 88: 9959–9963.
117.
SchneiderDJNordtTKSobelBE.Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes1999; 42: 1–7.
118.
AllisonBANilssonLKarpeFHamstenAErikssonP.Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. ArteriosclerThromb Vasc Biol1999; 19: 1354–1360.
119.
ErikssonPNilssonLKarpeFHamstenA.Very-low-density bull; lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol1999; 18: 20–26.
120.
In this work, the authors describe the effects of VLDL triglyceride on a specific component of the promoter for the PAI-1 gene.
121.
BybergLSiegbahnABerglundLMcKeiguePRenelandRLithellH.Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol1999; 18: 258–264.
122.
Calles-EscandonJMirzaSASobelBESchneiderDJ.Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes1999; 47: 290–293.
123.
An intravenous infusion of glucose and intralipid results in an elevated level of PAI-1 in normal subjects.
124.
SobelBE.Insulin resistance and thrombosis: a cardiologist's view. Am J Cardiol1999; 84: 37J–41J.
